Oncolytics Today Fall 2024

Publication Highlights

THE BISPECIFIC ANTIBODY REVOLUTION: Breakthroughs in research have led to a host of new cellular therapies. In this issue of Oncolytics Today, we take a look at recently approved BsAbs as well as advances in tumor-infiltrating lymphocytes, antibody-drug conjugates and CAR-T therapy. Page 51

What’s a PNET?: There’s a world of difference between the two primary pancreatic cancer variants. Page 32

PARP Inhibitors: Recent FDA-approved therapies offer novel treatment options for metastatic castration-resistant prostate cancer. Page 36

Additional Articles

Executive Council Message: ONCOLYTICS TODAY CONTINUES TO GROW, THANKS TO CONTRIBUTIONS FROM NCODA MEMBERS. Page 6

AI & Prescreening Hubs: Technology convergence spurs shift toward precision medicine. Page 8

Clinical Trial Equity: What must be done to provide access to the disadvantaged & underrepresented. Page 11

PBMs on the Hot Seat: Congressional hearings sharply critical of Pharmacy Benefit Managers. Page 14

Rising Cancer Costs: Practices must address financial toxicity by identifying resources for every patient. Page 17

Oncology Institute: ONCOLOGY INSTITUTE BRINGS TOGETHER MIP LEADERS AND INDUSTRY PARTNERS with a focus on health equity. Page 25

Nursing Community: NEW-START ADHERENCE BARRIERS ASSESSMENT AND DOCUMENTATION TEMPLATE FOR ONCOLOGY NURSES Page 27

PQI Podcast: BEYOND THE FIREWALL: ENHANCING CYBERSECURITY IN ONCOLOGY CARE. Page 29

BCPS Certification Update: Prepping for the latest Board-Certified Pharmacotherapy Specialist exam. Page 31

Cancer & Diabetes: How to manage patients with chronic myeloproliferative neoplasms. Page 41

New Drug Roundup: FDA ANNOUNCES APPROVAL OF 11 NEW ORAL ONCOLYTICS. Page 83

Hypersensitivity Research: Identifying risk factors for reactions to pegylated-liposomal doxorubicin. Page 89

Long COVID: Lingering effects impact healthcare, oncology and the disadvantaged. Page 94

Medicare Reforms for 2025: New caps limit out-of-pocket spending, but patients will still need assistance. Page 99

Large Language Models: Ever-improving AI systems offer new opportunities for researchers, practices and cancer patients. Page 101

Investigational Drug Services: Tennessee Oncology’s new research facility will offer state-of-the-art examination of novel drug integrity. Page 105

Partnering With Pharma: NCODA’s Strategy & Development team discusses the five traits needed for creating an effective relationship. Page 108

What’s Your Risk?: Cancer predisposition variants in apparently healthy individuals are not always cause for alarm. Page110

Putting Patients First: It’s important to let those diagnosed with cancer know that it’s not their fault

Final Word: BREAKTHROUGHS IN ONCOLOGY ARE BECOMING ROUTINE THANKS TO NEW CELLULAR THERAPIES. Page 118